Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D; Ken Marek on behalf of the Critical Path for Parkinson’s Consortium.

J Parkinsons Dis. 2019 Sep 13. doi: 10.3233/JPD-199003. [Epub ahead of print] No abstract available.

PMID:
31524182
2.

Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration.

Ren X, Lin J, Luo S, Goetz CG, Stebbins GT, Cubo E.

Parkinsonism Relat Disord. 2019 Aug 31. pii: S1353-8020(19)30375-X. doi: 10.1016/j.parkreldis.2019.08.019. [Epub ahead of print]

PMID:
31495732
3.

Sensory Tricks Are Associated with Higher Sleep-Related Quality of Life in Cervical Dystonia.

Benadof CN, Cisneros E, Appelbaum MI, Stebbins GT, Comella CL, Peterson DA.

Tremor Other Hyperkinet Mov (N Y). 2019 Jun 17;9. doi: 10.7916/4q53-vt23. eCollection 2019.

4.

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K; Critical Path for Parkinson’s Consortium.

J Parkinsons Dis. 2019;9(3):553-563. doi: 10.3233/JPD-191648.

5.

Reliability, feasibility and satisfaction of telemedicine evaluations for Cervical Dystonia.

Fraint A, Stebbins GT, Pal G, Comella CL.

J Telemed Telecare. 2019 Jun 17:1357633X19853140. doi: 10.1177/1357633X19853140. [Epub ahead of print] No abstract available.

PMID:
31208263
6.

Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations.

Evans AH, Okai D, Weintraub D, Lim SY, O'Sullivan SS, Voon V, Krack P, Sampaio C, Post B, Leentjens AFG, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A; Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee.

Mov Disord. 2019 Jun;34(6):791-798. doi: 10.1002/mds.27689. Epub 2019 May 28. Review.

PMID:
31136681
7.

The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.

Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C, Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating Scales Program Electronic Development Ad-Hoc Committee.

Mov Disord. 2019 May;34(5):676-681. doi: 10.1002/mds.27673. Epub 2019 Mar 22. No abstract available.

PMID:
30901492
8.

Clinimetric Properties of the Fragile X-associated Tremor Ataxia Syndrome Rating Scale.

Hall DA, Stebbins GT, Jacquemont S, Berry-Kravis E, Goetz CG, Hagerman R, Zhang L, Leehey MA.

Mov Disord Clin Pract. 2019 Jan 22;6(2):120-124. doi: 10.1002/mdc3.12708. eCollection 2019 Feb.

PMID:
30838310
9.

Telemedicine vs Office Visits in a Movement Disorders Clinic: Comparative Satisfaction of Physicians and Patients.

Hanson RE, Truesdell M, Stebbins GT, Weathers AL, Goetz CG.

Mov Disord Clin Pract. 2018 Dec 13;6(1):65-69. doi: 10.1002/mdc3.12703. eCollection 2019 Jan.

PMID:
30746418
10.

Missing Data in the Unified Dysksinesia Rating Scale (UDysRS).

Luo S, Ren X, Han W, Goetz CG, Stebbins GT.

Mov Disord Clin Pract. 2018 Aug 24;5(5):523-526. doi: 10.1002/mdc3.12642. eCollection 2018 Sep-Oct.

11.

Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations.

Pavy-Le Traon A, Cotterill N, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Rascol O, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Oct 25;5(5):479-491. doi: 10.1002/mdc3.12636. eCollection 2018 Sep-Oct. Review.

PMID:
30515437
12.

White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease.

Bledsoe IO, Stebbins GT, Merkitch D, Goldman JG.

Neurology. 2018 Dec 11;91(24):e2244-e2255. doi: 10.1212/WNL.0000000000006646. Epub 2018 Nov 14.

PMID:
30429273
13.

Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Mestre TA, Busse M, Davis AM, Quinn L, Rodrigues FB, Burgunder JM, Carlozzi NE, Walker F, Ho AK, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 May 9;5(4):361-372. doi: 10.1002/mdc3.12617. eCollection 2018 Jul-Aug.

14.

Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the Movement Disorder Society Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Jan 3;5(2):111-117. doi: 10.1002/mdc3.12571. eCollection 2018 Mar-Apr.

15.

Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating Scale.

Akbostanci MC, Bayram E, Yilmaz V, Rzayev S, Özkan S, Tokcaer AB, Saka E, Durmaz Celik FN, Barut BÖ, Tüfekcioglu Z, Acarer A, Balaban H, Erer S, Dogu O, Kibaroglu S, Aydin N, Hanagasi H, Elibol B, Emre M, Stebbins GT, Goetz CG.

Mov Disord Clin Pract. 2017 Nov 16;5(1):54-59. doi: 10.1002/mdc3.12556. eCollection 2018 Jan-Feb.

16.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14. Review.

PMID:
30216541
17.

Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Skorvanek M, Martinez-Martin P, Stebbins GT, Goetz CG.

Mov Disord. 2018 Jul;33(7):1189-1190. doi: 10.1002/mds.27452. No abstract available.

PMID:
30153386
18.

What influences placebo and nocebo responses in Parkinson's disease?

Witek N, Stebbins GT, Goetz CG.

Mov Disord. 2018 Aug;33(8):1204-1212. doi: 10.1002/mds.27416. Epub 2018 Aug 22. Review.

PMID:
30132980
19.

Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients.

Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Aviles-Olmos I, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Benchetrit E, Benoit C, Bergareche-Yarza A, Cervantes-Arriaga A, Chade A, Cormier F, Datieva V, Gallagher DA, Garretto N, Gdovinova Z, Gershanik O, Grofik M, Han V, Kadastik-Eerme L, Kurtis MM, Mangone G, Martinez-Castrillo JC, Mendoza-Rodriguez A, Minar M, Moore HP, Muldmaa M, Mueller C, Pinter B, Poewe W, Rallmann K, Reiter E, Rodriguez-Blazquez C, Singer C, Valkovic P, Goetz CG, Stebbins GT.

Parkinsonism Relat Disord. 2018 Jul;52:83-89. doi: 10.1016/j.parkreldis.2018.03.027. Epub 2018 Mar 28.

PMID:
29625875
20.

Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life.

Mestre TA, Carlozzi NE, Ho AK, Burgunder JM, Walker F, Davis AM, Busse M, Quinn L, Rodrigues FB, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2018 May;33(5):742-749. doi: 10.1002/mds.27317. Epub 2018 Mar 23. Review.

21.

Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.

Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP.

Mov Disord. 2018 Apr;33(4):503-510. doi: 10.1002/mds.27323. Epub 2018 Feb 28. Review.

PMID:
29488270
22.

Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P.

Mov Disord. 2018 Mar;33(3):499-500. doi: 10.1002/mds.27339. Epub 2018 Feb 20. No abstract available.

PMID:
29460975
23.

Validation study of the hoehn and yahr scale included in the MDS-UPDRS.

Martinez-Martin P, Skorvanek M, Rojo-Abuin JM, Gregova Z, Stebbins GT, Goetz CG; members of the QUALPD Study Group.

Mov Disord. 2018 Apr;33(4):651-652. doi: 10.1002/mds.27242. Epub 2018 Jan 11. No abstract available.

PMID:
29322548
24.

Rating scales for cognition in Huntington's disease: Critique and recommendations.

Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2018 Feb;33(2):187-195. doi: 10.1002/mds.27227. Epub 2017 Dec 26. Review.

PMID:
29278291
25.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13.

26.

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P; members of the MDS Rating Scales Review Committee.

Mov Disord. 2018 Feb;33(2):208-218. doi: 10.1002/mds.27233. Epub 2017 Nov 23. Review.

PMID:
29168899
27.

Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Zitser J, Peretz C, Ber David A, Shabtai H, Ezra A, Kestenbaum M, Brozgol M, Rosenberg A, Herman T, Balash Y, Gadoth A, Thaler A, Stebbins GT, Goetz CG, Tilley BC, Luo ST, Liu Y, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2017 Dec;45:7-12. doi: 10.1016/j.parkreldis.2017.09.012. Epub 2017 Sep 24.

28.

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.

Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA.

Mov Disord. 2017 Sep;32(9):1335-1336. doi: 10.1002/mds.27092. Epub 2017 Jun 24. No abstract available.

PMID:
28646494
29.

Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS).

Luo S, Liu Y, Teresi JA, Stebbins GT, Goetz CG.

Mov Disord. 2017 Aug;32(8):1244-1249. doi: 10.1002/mds.27058. Epub 2017 Jun 1.

30.

Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society- Unified Parkinson's Disease Rating Scale.

Yu RL, Wu RM, Chan AY, Mok V, Wu YR, Tilley BC, Luo S, Wang L, LaPelle NR, Stebbins GT, Goetz CG.

Mov Disord Clin Pract. 2017 Jan-Feb;4(1):68-77. doi: 10.1002/mdc3.12349. Epub 2016 Apr 8.

31.

Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.

Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Foltynie T, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Aviles-Olmos I, Benchetrit E, Benoit C, Bergareche-Yarza A, Cervantes-Arriaga A, Chade A, Cormier F, Datieva V, Gallagher DA, Garretto N, Gdovinova Z, Gershanik O, Grofik M, Han V, Huang J, Kadastik-Eerme L, Kurtis MM, Mangone G, Martinez-Castrillo JC, Mendoza-Rodriguez A, Minar M, Moore HP, Muldmaa M, Mueller C, Pinter B, Poewe W, Rallmann K, Reiter E, Rodriguez-Blazquez C, Singer C, Tilley BC, Valkovic P, Goetz CG, Stebbins GT.

Mov Disord Clin Pract. 2017 Mar 11;4(4):536-544. doi: 10.1002/mdc3.12476. eCollection 2017 Jul-Aug.

32.

Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations".

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2017 Mar;32(3):482. doi: 10.1002/mds.26954. Epub 2017 Mar 3. No abstract available.

PMID:
28256103
33.

Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease.

Goldman JG, Bledsoe IO, Merkitch D, Dinh V, Bernard B, Stebbins GT.

Neurology. 2017 Mar 28;88(13):1265-1272. doi: 10.1212/WNL.0000000000003764. Epub 2017 Feb 24.

34.

Systematic review of severity scales and screening instruments for tics: Critique and recommendations.

Martino D, Pringsheim TM, Cavanna AE, Colosimo C, Hartmann A, Leckman JF, Luo S, Munchau A, Goetz CG, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2017 Mar;32(3):467-473. doi: 10.1002/mds.26891. Epub 2017 Jan 10. Review.

35.

Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.

Goetz CG, Liu Y, Stebbins GT, Wang L, Tilley BC, Teresi JA, Merkitch D, Luo S.

Mov Disord. 2016 Dec;31(12):1865-1873. doi: 10.1002/mds.26847. Epub 2016 Nov 7.

36.

Knowledge gaps and research recommendations for essential tremor.

Hopfner F, Haubenberger D, Galpern WR, Gwinn K, Van't Veer A, White S, Bhatia K, Adler CH, Eidelberg D, Ondo W, Stebbins GT, Tanner CM, Helmich RC, Lenz FA, Sillitoe RV, Vaillancourt D, Vitek JL, Louis ED, Shill HA, Frosch MP, Foroud T, Kuhlenbäumer G, Singleton A, Testa CM, Hallett M, Elble R, Deuschl G.

Parkinsonism Relat Disord. 2016 Dec;33:27-35. doi: 10.1016/j.parkreldis.2016.10.002. Epub 2016 Oct 4. Review.

37.

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.

Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2016 Oct 1;73(10):1217-1224. doi: 10.1001/jamaneurol.2016.2245.

38.

Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Ferreira JJ, Mahlknecht P, Tumas V, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P; Members of the MDS Committee on Rating Scales Development.

Mov Disord. 2016 Oct;31(10):1466-1478. doi: 10.1002/mds.26675. Review.

PMID:
27296904
39.

Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.

Shulman LM, Armstrong M, Ellis T, Gruber-Baldini A, Horak F, Nieuwboer A, Parashos S, Post B, Rogers M, Siderowf A, Goetz CG, Schrag A, Stebbins GT, Martinez-Martin P.

Mov Disord. 2016 Oct;31(10):1455-1465. doi: 10.1002/mds.26649. Review.

PMID:
27193358
40.

Association of the Fractal Dimension of Retinal Arteries and Veins with Quantitative Brain MRI Measures in HIV-Infected and Uninfected Women.

Crystal HA, Holman S, Lui YW, Baird AE, Yu H, Klein R, Rojas-Soto DM, Gustafson DR, Stebbins GT.

PLoS One. 2016 May 9;11(5):e0154858. doi: 10.1371/journal.pone.0154858. eCollection 2016.

41.

Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology.

Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, McDonald WM, Marsh L, Rosen AR, Waliczek T, Wright LJ, Galpern WR, Stebbins GT.

Mov Disord Clin Pract. 2015 Jun;2(2):135-141. Epub 2015 Apr 6.

42.

Clinimetric testing of the comprehensive cervical dystonia rating scale.

Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, Adler CA, Barbano RL, Factor SA, Goetz CG, Jankovic J, Reich SG, Rodriguez RL, Severt WL, Zurowski M, Fox SH, Stebbins GT.

Mov Disord. 2016 Apr;31(4):563-9. doi: 10.1002/mds.26534. Epub 2016 Mar 12.

43.

Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease.

Diederich NJ, Goldman JG, Stebbins GT, Goetz CG.

Mov Disord. 2016 Jan;31(1):11-22. doi: 10.1002/mds.26460. Epub 2015 Dec 9. Review.

PMID:
26650182
44.

Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis.

Hall DA, Stebbins GT, Litvan I, Bordelon Y, Riley DE, Leverenz J, Standaert DG.

Mov Disord Clin Pract. 2015 Oct 20;3(1):65-67. doi: 10.1002/mdc3.12243. eCollection 2016 Jan-Feb.

45.

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Mov Disord. 2016 Jan;31(1):95-102. doi: 10.1002/mds.26359. Epub 2015 Aug 21.

46.

Erratum: Emerging topics in FXTAS.

Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe JA, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA.

J Neurodev Disord. 2015;7(1):13. doi: 10.1186/s11689-015-9108-7. Epub 2015 Apr 8.

47.

Development and validation of a clinical scale for rating the severity of blepharospasm.

Defazio G, Hallett M, Jinnah HA, Stebbins GT, Gigante AF, Ferrazzano G, Conte A, Fabbrini G, Berardelli A.

Mov Disord. 2015 Apr;30(4):525-30. doi: 10.1002/mds.26156.

48.

Cognitive profile of LRRK2-related Parkinson's disease.

Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP.

Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.

49.

Handling missing values in the MDS-UPDRS.

Goetz CG, Luo S, Wang L, Tilley BC, LaPelle NR, Stebbins GT.

Mov Disord. 2015 Oct;30(12):1632-8. doi: 10.1002/mds.26153. Epub 2015 Feb 4.

50.

Emerging topics in FXTAS.

Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe J, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA.

J Neurodev Disord. 2014;6(1):31. doi: 10.1186/1866-1955-6-31. Epub 2014 Jul 30. Review. Erratum in: J Neurodev Disord. 2015;7(1):13.

Supplemental Content

Loading ...
Support Center